Compare CRTO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | CGEM |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.9M | 904.7M |
| IPO Year | 2013 | 2020 |
| Metric | CRTO | CGEM |
|---|---|---|
| Price | $18.30 | $16.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $34.00 | $30.13 |
| AVG Volume (30 Days) | 367.1K | ★ 956.5K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $2,296,692,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | $5.20 |
| P/E Ratio | $122.23 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.58 | $5.68 |
| 52 Week High | $27.32 | $16.74 |
| Indicator | CRTO | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 62.01 |
| Support Level | $18.04 | $11.92 |
| Resistance Level | $19.98 | N/A |
| Average True Range (ATR) | 0.60 | 1.03 |
| MACD | 0.23 | 0.08 |
| Stochastic Oscillator | 82.82 | 89.05 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.